FDA Signals Regulatory Flexibility With Accelerated Approval of Rare Disease Drug

(MedPage Today) — The FDA granted accelerated approval to tividenofusp alfa (Avlayah) for the treatment of mucopolysaccharidosis type II (MPS II), a rare disease also known as Hunter syndrome, the agency announced Wednesday.
The IV infusion…